United Health Products, Inc 8-K, filed May 8, 2025
United Health Products, Inc. (UEEC)
About this 8-K
United Health Products, Inc filed this 8-K on May 8, 2025, reporting on events of May 1, 2025.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter) |
|
| |||
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code) |
(
Registrant’s telephone number, including area code
___________________________________________________
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
N/A |
| N/A |
| N/A |
Item 8.01. Other Events.
On May 1, 2025, United Health Products, Inc. (the “Company”) issued a press release announcing that its common stock had been upgraded from the OTC Pink to the OTCQB Venture Market.
The press release also provided an update regarding the Company’s Premarket Approval application with the U.S. Food and Drug Administration for its CelluSTAT® gauze product. We refer you to the risk factors in Part I Item 1A in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and in Part II Item 1A of the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2025 for a discussion of the risks relating to our Premarket Approval application.
A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number | Description | |
|
|
|
| ||
104 |
| Cover Page Interactive Data File (embedded within the Inline XBRL Document) |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
United Health Products, Inc. |
| ||
| |||
Dated: May 8, 2025 | By: | /s/ Brian Thom | |
| Brian Thom Chief Executive Officer | ||
| 3 |
EXHIBIT 99.1
United Health Products Announces OTCQB Uplisting and FDA Update
Mount Laurel, New Jersey – May 1, 2025 – United Health Products, Inc. (OTCQB: UEEC) is pleased to announce that it has been approved to have its common shares uplisted from the OTC “Pink” market to the OTCQB Venture Market (“OTCQB”). The successful uplisting is effective May 1, 2025 and the company’s common shares will continue to trade under the ticker symbol “UEEC”.
UHP believes the uplisting will boost visibility to a broader universe of investors and provide improved liquidity for its stock as the company advances its FDA application for Premarket Approval of its CelluSTAT Hemostatic Gauze. The OTCQB is the premier marketplace for developing companies, including those in the medical technology sector.
Brian Thom, UHP’s Chief Executive Officer, commented, “Uplisting to the OTCQB Venture Market is an important milestone for our company and reflects UHP’s commitment to improving corporate transparency, increasing share trading liquidity, and expanding the universe of potential investors.”
The OTCQB is a trading platform operated by the OTC Markets Group Inc. that is designed for developing and entrepreneurial-stage companies, and is considered by the SEC to be an “established public market”. Companies listed on the OTCQB are current in their SEC financial reporting and complete an annual verification and management certification process. Additional information about the OTC Markets Group Inc. and the OTCQB can be found at www.otcmarkets.com.
Regulatory Update:
On April 25, the Food & Drug Administration (FDA) gave notice to the company that it declined to approve the company’s Investigational Device Exemption (IDE) application to conduct the previously announced, follow on clinical study. The FDA did not cite any deficiencies from its review of the proposed clinical study design. Rather, it cited certain findings from one of the two Bioresearch Monitoring (BIMO) audits of UHP’s initial 2019 clinical study that were conducted in 3Q/2024, and which the company had responded to on October 25, 2024 and again on April 14, 2025. UHP and the FDA are scheduling a teleconference in the next 10 days that the company hopes will resolve this issue and allow the clinical study to proceed. In the interim, the company continues to advance those clinical study tasks that can be accomplished prior to the IDE approval.
There can be no assurance that the FDA Premarket Approval application will be granted.
About United Health Products -- UHP has developed and patented a Neutralized Regenerated Cellulose hemostatic agent. CelluSTAT Hemostatic Gauze is an all-natural product designed to control mild to moderate bleeding. UHP is seeking approval to access the human surgical market.
For more information on UHP visit the company’s new website: www.uhpcorp.com or contact the company at info@uhpcorp.com.
The company can also be reached by phone or text message at 475.755.1005.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.